BIIB trade ideas: every closed DuckWise idea on Biogen Inc.

DuckWise has published 1 idea on Biogen Inc. (BIIB, Stock) that has closed between November 2020 and January 2021. Each is listed below with the levels published before the position was taken and its result at close — 1 in profit, 0 at a loss.

1closed idea

1 / 0in profit / at a loss

+27.12%average result

81 daystypical holding period

Opened	Closed	Side	Entry	Stop	Projection	Close	Result	Days
Nov 9, 2020	Jan 29, 2021	Long	228	—	295	289.84	+27.12%	81

Prices in US dollars. Result is the price change from the published entry to the published close, before fees, taxes and slippage. How results are counted.

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. Does not pay dividends.

These are closed ideas, published for the record. They are general and impersonal research, not a recommendation to buy or sell BIIB or any other security.